Suppliers / Hubei Enoray Biopharmaceutical

Hubei Enoray Biopharmaceutical

China Updated 9 July 2026

Hubei Enoray Biopharmaceutical is an API manufacturer based in China. It holds 3 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 13 March 2025 as NAI.

3
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 13 March 2025 NAI US FDA
  • 27 July 2017 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3010165284

What they file, and where

Molecule Regulators Docs
Heparin Sodium US FDA 2
Enoxaparin US FDA 1

Also appears on these molecule pages

Enoxaparin API Heparin API

Filings and GMP by regulator

Regulator Filings GMP certificates
INVIMA (CO) 1 None
US FDA None 1

Questions about Hubei Enoray Biopharmaceutical

Does Hubei Enoray Biopharmaceutical hold a US DMF or a CEP?
Hubei Enoray Biopharmaceutical holds 3 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Hubei Enoray Biopharmaceutical FDA-registered?
One site operated by Hubei Enoray Biopharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Hubei Enoray Biopharmaceutical's last inspection go?
The most recent inspection on record closed on 13 March 2025 as NAI (No Action Indicated: nothing objectionable was found). 2 inspections are on file.
Where does Hubei Enoray Biopharmaceutical manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Hubei Enoray Biopharmaceutical make?
2 molecules are on record against Hubei Enoray Biopharmaceutical, including Heparin Sodium and Enoxaparin. Each links through to that molecule's full manufacturer list.
Which regulators recognise Hubei Enoray Biopharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Hubei Enoray Biopharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 13 March 2025.

Comparable suppliers

Gland Pharma shares 2 molecules Dongying Tiandong Pharmaceutical shares 2 molecules Hebei Changshan Biochemical Pharmaceutical shares 2 molecules Nanjing King-Friend Biochemical Pharmaceutical shares 2 molecules Yantai Dongcheng Biochemicals Co.,Ltd shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates